[1] |
Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691. DOI: 10.1001/jamaoncol.2017.3055.
|
[2] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
|
[3] |
ZHENG R, ZENG H, ZHANG S, et al. Estimates of cancer incidence and mortality in China, 2013[J]. Chin J Cancer, 2017, 36(1): 66. DOI: 10.1186/s40880-017-0234-3.
|
[4] |
WU T, CHEN L. New advances in the precision diagnosis and treatment of liver cancer[J]. J Clin Hepatol, 2022, 38(3): 497-498. DOI: 10.3969/j.issn.1001-5256.2022.03.001.
吴彤, 陈磊. 肝癌精准诊疗新进展[J]. 临床肝胆病杂志, 2022, 38(3): 497-498. DOI: 10.3969/j.issn.1001-5256.2022.03.001.
|
[5] |
LI Z, ZHU JY. Interpretation of Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(5): 1027-1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.
李照, 朱继业. 《原发性肝癌诊疗指南(2022年版)》解读[J]. 临床肝胆病杂志, 2022, 38(5): 1027-1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.
|
[6] |
CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo- controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7.
|
[7] |
KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
|
[8] |
LYU N, KONG Y, PAN T, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread[J]. J Vasc Interv Radiol, 2019, 30(3): 349-357. e2. DOI: 10.1016/j.jvir.2018.09.004.
|
[9] |
HE MK, LIANG RB, ZHAO Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
|
[10] |
KOKUDO N, HASEGAWA K, AKAHANE M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, 45(2). DOI: 10.1111/hepr.12464.
|
[11] |
IKEDA M, OKUSAKA T, FURUSE J, et al. A multi-institutional phase Ⅱ trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2013, 72(2): 463-470. DOI: 10.1007/s00280-013-2222-x.
|
[12] |
NOUSO K, MIYAHARA K, UCHIDA D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7): 1904-1907. DOI: 10.1038/bjc.2013.542.
|
[13] |
Tumor Interventional Expert Committee of Chinese Anti-Cancer Association. Chinese tumor intervention expert consensus on the application principles of transcatheter arterial infusion chemotherapy[J]. J Intervent Radiol, 2017, 26(11): 963-970. DOI: 10.3969/j.issn.1008-794X.2017.11.001.
中国抗癌协会肿瘤介入专家委员会. 经导管动脉灌注化疗药物应用原则——中国肿瘤介入专家共识[J]. 介入放射学杂志, 2017, 26(11): 963-970. DOI: 10.3969/j.issn.1008-794X.2017.11.001.
|
[14] |
ZHAO M. Hepatic arterial infusion Chemotherapy in the Era of Precise[J]. J Sun Yat-Sen Univ(Medical Sciences), 2019, 40(5): 648-656. DOI: 1672-3554(2019)05-0648-09.
赵明. 精准医疗时代背景下的肝动脉灌注化疗[J]. 中山大学学报(医学科学版), 2019, 40(5): 648-656. DOI: 1672-3554(2019)05-0648-09.
|
[15] |
LI QJ, HE MK, CHEN HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A Randomized Phase Ⅲ Trial[J]. J Clin Oncol, 2022, 40(2): 150-160. DOI: 10.1200/JCO.21.00608.
|
[16] |
SIDAWAY P. FOLFOX-HAIC active in large HCC[J]. Nat Rev Clin Oncol, 2022, 19(1): 5. DOI: 10.1038/s41571-021-00577-y.
|
[17] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
|
[18] |
Chinese College of Transplant Doctors, Liver Transplantation Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese clinical practice guidelines on liver transplantation for hepatocellular carcinoma (2021edition)[J]. Chin J Dig Surg, 2022, 21(4): 433-443. DOI: 10.3760/cma.j.cn115610-20220316-00135.
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J]. 中华消化外科杂志, 2022, 21(4): 433-443. DOI: 10.3760/cma.j.cn115610-20220316-00135.
|
[19] |
LIU YY. New progress of hepatocellular carcinoma treatment[J]. Chin J Dig Surg, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.
刘允怡. 肝细胞癌治疗的新发展[J]. 中华消化外科杂志, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.
|
[20] |
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
|
[21] |
Liver Cancer Professional Committee of Chinese Anti-Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition)[J]. J Chin J Dig Surg, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288.
中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288.
|
[22] |
HE MK, LE Y, LI QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83. DOI: 10.1186/s40880-017-0251-2.
|
[23] |
HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
|
[24] |
MEI J, LI SH, LI QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 167-176. DOI: 10.2147/JHC.S298538.
|
[25] |
MEI J, TANG YH, WEI W, et al. Hepatic arterial infusion chemotherapy combined With PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 618206. DOI: 10.3389/fonc.2021.618206.
|
[26] |
WU YB, WU ZQ, HUANG JL, et al. Hepatic arterial infusion chemotherapy for primary liver cancer effect of portal vein tumor thrombus[J]. China Health Standard Management, 2022, 13(12): 109-112. DOI: 10.3969/j.issn.1674-9316.2022.12.027.
吴义波, 吴卓琼, 黄洁丽, 等. 肝动脉灌注化疗对原发性肝癌合并门静脉癌栓的效果[J]. 中国卫生标准管理, 2022, 13(12): 109-112. DOI: 10.3969/j.issn.1674-9316.2022.12.027.
|
[27] |
KE YP, YE SG, LU SB. Short-term efficacy of transcatheter arterial embolization combined with FOLFOX4 regimen of continuous arterial infusion chemotherapy on hepatocellular carcinoma patients with portal vein tumor thrombus[J]. China Med Pharm, 2022, 12(16): 156-159. DOI: 10.3969/j.issn.2095-0616.2022.16.040.
柯映平, 叶绍光, 卢舜彬. 肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗对肝细胞癌门静脉癌栓患者的近期疗效[J]. 中国医药科学, 2022, 12(16): 156-159. DOI: 10.3969/j.issn.2095-0616.2022.16.040.
|